Document is current
Any future updates will be listed below
-
Authors
Saavedra, Djairo Pastor https://orcid.org/0000-0002-2664-3800
Nobre, Maurício Lisboa https://orcid.org/0000-0003-4932-3137
Guimarães, Rafael Alves https://orcid.org/0000-0001-5171-7958
Fogaça, Matheus Bernardes Torres https://orcid.org/0000-0002-8465-6124
Goulart, Isabela Maria Bernardes https://orcid.org/0000-0003-2319-3223
Barreto, Jaison Antônio
de Souza, Vânia Nieto Brito https://orcid.org/0000-0002-4963-769X
Jeronimo, Selma Maria Bezerra https://orcid.org/0000-0002-4784-9904
Amorim, Francianne Medeiros https://orcid.org/0000-0001-9474-5764
da Silva, Tatiana Pereira https://orcid.org/0000-0002-4016-3002
Pinheiro, Roberta Olmo https://orcid.org/0000-0001-8471-4227
Stefani, Mariane Martins de Araújo https://orcid.org/0000-0001-7874-4315
Bührer-Sékula, Samira https://orcid.org/0000-0002-5984-7770
-
Funding
Funding for this research was provided by:
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (88887.940507/2024-00)
Fundação de Amparo a Pesquisa do Estado do Amazonas (010/2023)
National Health Fund (23070.047965/2019-56)
- License Information
-
More Information
Article History
Received: 22 November 2024
Accepted: 10 February 2025
First Online: 15 February 2025
Declarations
:
: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Research Ethics Committee of Brazil (CAAE:38949520.0.0000.5078).
: Informed consent was obtained from all subjects involved in the study.
: The authors disclose that this multicenter study compares the Bioclin Fast ML Flow Hanseníase commercial test with other diagnostic methods. It is important to mention that the lead researcher of the coordinating center, S.B.S., has previously been involved in the technology transfer to Quibasa—Química Básica LTDA, the company that owns this product. This relationship has been acknowledged to maintain transparency and uphold the integrity of the study’s results.
